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Abstract The chemical structures of morphine and its metab-
olites are closely related to the clinical effects of drugs (analge-
sia and side-effects) and to their capability to cross the Blood
Brain Barrier (BBB). Morphine-6-glucuronide (M6G) and
Morphine-3-glucuronide (M3G) are both highly hydrophilic,
but only M6G can penetrate the BBB; accordingly, M6G is
considered a more attractive analgesic than the parent drug and
the M3G. Several hypotheses have been made to explain these
differences. In this review we will discuss recent advances in
the field, considering brain disposition of M6G, UDP-
glucoronosyltransferases (UGT) involved in morphine metab-
olism, UGT interindividual variability and transport proteins.
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Introduction
The blood-brain barrier (BBB) is a dynamic interface between
the blood and the brain. It eliminates (toxic) substances from
the endothelial compartment and supplies the brain with
nutrients and other (endogenous) compounds. It can be consid-
ered as an organ protecting the brain: its integrity is essential for
brain homeostasis, and many carrier-/receptor-mediated trans-
portsystemsplayanimportantroleinmaintainingthisintegrity.
Even with minimal disruption of the BBB, circulating neuro-
toxins, hormones and ions coulde n t e rt h eb r a i na n di n t e r f e r e
with the internal milieu, thus resulting in potential damage to
neurons (Johansson et al. 1990;M u r a k a m ie ta l .1997).
Drug transport to the brain depends on various parame-
ters: for drugs that can easily pass the BBB, local blood flow
and capillary flow area are limiting factors, whereas for
other drugs BBB permeability is restrictive.
Plasma-protein binding controls both the free (unbound)
fraction of drugs/compounds and their distribution in the
blood; these two factors influence the amount of drugs/
compounds able to pass the BBB. However, it has been
observed that many plasma binding proteins (albumin,
alpha-acid-glycoprotein, globulins, high-density lipopro-
tein, low-density lipoprotein) can “donate” ligands to the
BBB (De Boer et al. 2003).
Systemic metabolism of drugs takes place mainly in the
liver but it can also occur during BBB transport, because
many enzymes are present in the brain capillaries (Minn et
al. 1991). Before drugs enter the central nervous system
(CNS), enzymes can transform them into metabolites that
can be more or less effective or even toxic.
The physical-chemical characteristics of drugs (e.g. hydro-
philicity, lipophilicity, hydrogen bonding potential) largely
determine their passive transport across the BBB, through
hydrophilic paracellular and lipophilic transcellular transport.
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The main metabolic pathway of morphine in mammals is
glucuronidation catalyzed by UDP-glucuronosyltransferase
(UGT) enzymes. The human UGTs identified so far have
been subdivided into 4 families (UGT1, 2, 3, and 8) accord-
ing to their sequence homologies (Di et al. 2009). The
ability to glucuronidate morphine varies between individu-
als, and polymorphisms of UGT2B7 have been proposed as
a possible cause of this variability (Holthe et al. 2002).
Among UGTs, UGT2B7 represents the major isoform re-
sponsible for the 3- and 6-glucuronidation of morphine in
humans (Fig. 1).
The UGT2 family members (subdivided into UGT2A
and 2B) derive from transcription of separate genes located
on chromosome 4q13. The UGT2A subfamily includes 3
members, i.e. UGT2A3, which is coded by a single gene of
6 exons, and UGT2A1 and UGT2A2, which share the same
C-terminal sequence but have differing N-terminal sequen-
ces. UGT2A1 and UGT2A2 proteins arise by the differential
splicing of a variable first exon to the same set of 5 down-
stream exons. UGT2B subfamily includes 7 genes as well as
5 pseudogenes. UGT2B7 variants have been shown to be
related to altered drug metabolism and disease risk (Di et al.
2009). For example, a promoter variant of UGT2B7 gene is
associated with significantly reduced glucuronidation of
morphine in sickle cell disease and contributes to the vari-
ability observed in the hepatic clearance of morphine in
patients. Innocenti et al. (2008) have recently supported
the hypothesis that a common UGT2B7 haplotype (com-
prised of 10 SNPs) increases enzyme activity by regulating
mRNA expression; this might explain part of the phenotypic
variability in the pharmacokinetics and pharmacodynamics
of UGT2B7 substrates (Innocenti et al. 2008)
Morphine and metabolites
The major morphine metabolite, morphine-3-glucuronide
(M3G), although analgesically inactive, has been reported to
antagonize morphine and to produce stimulatory effects, such
as myoclonus, seizure and allodynia (Smith 2000). On the
other hand, the minor metabolite, morphine-6-glucuronide
(M6G), is much more analgesic than morphine.
Morphine is primarily metabolized in the liver by
uridine-5′-diphosphate (UDP) glucoronosyltransferase, with
specific affinity for the UGT2B7 isoenzyme. This isoen-
zyme is responsible for the formation of both glucuronide
species, but at different amounts (5 times more M3G than
M6G). Researchers postulated the presence of another met-
abolic isoenzyme that largely forms M3G. Although in vitro
results have indicated a possible role of UGT1A1 in the
formation of M3G, in vivo UGT2B7 isoenzyme remains the
primary metabolic enzyme for morphine (Stone et al. 2003).
The different formation of M3G and M6G metabolites
(Fig. 1) is likely due to physicochemical and steric issues
that affect the binding of morphine to the phase II enzyme
(Coffman et al. 1998).
UGT2B7 is also responsible for the metabolism of several
endogenous and exogenous compounds, especially steroid
hormones and bilirubin in the newborn. These compounds
are competitive substrates for UGT2B7 and can reduce the
formation of morphine-conjugate metabolites.
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Fig. 1 Morphine-3- and
morphine-6-glucuronidation by
UGT2B7
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been shown to metabolize morphine at nanomolar concen-
trations to M3G and M6G; therefore, M6G can be formed
directly in the CNS and seems to penetrate the BBB at a
greater rate than the M6G produced in the liver (Yamada et
al. 2003). Interestingly, the M3G/M6G ratio produced by
the brain homogenates has been found to be directly asso-
ciated with morphine concentration. Lower concentrations
of morphine corresponded to a lower M3G/M6G ratio,
perhaps due to the preferential formation of M6G by
UGT2B7 (Yamada et al. 2003). Although UGT2B7 appears
to play a role in M6G formation from endogenous mor-
phine, the enzymology of this metabolism in the brain needs
to be more thoroughly elucidated. Moreover, the brain UGT
isoforms responsible for morphine glucuronidation may be
different from the hepatic ones.
Several studies have been performed on morphine-
metabolizing enzymes and on the μ-opioid receptor, in
order to detect genetic variants possibly contributing to
interindividual variability in morphine pharmacology. The
UGT2B7 H288Y polymorphism does not seem to account
for the significant variations in glucuronide-to-morphine
ratio seen in cancer patients (Coughtrie et al. 1989). On
the contrary, global UGT activity is apparently modulated
by a series of genetic polymorphisms (Coffman et al.
1998). Variants in μ-opioid receptor gene (OPRM1) play
an important role in mediating morphine activity: this
gene is highly polymorphic, and the rs1799971 SNP in
exon 1 seems to be associated with a decreased thera-
peutic efficacy. In particular, the 118 G homozygotes
require higher morphine doses for pain relief than heter-
ozygotes or non-carriers, showing increased risks of in-
toxication and respiratory depression. The explanation
could be related to clinically measurable differences in
M6G effects (Lötsch et al. 2002a, b; Lötsch and Geis-
slinger 2005; Romberg et al. 2005). Similarly, COMT
(Catechol-O-MethylTransferase) polymorphisms have to
be taken into account for morphine dose modulation:
the enzyme is responsible for dopamine, norepinephrine
and epinephrine metabolism. Its Val158Met polymor-
phism (rs4680) is related with enzyme activity since
methionine causes a three times reduction of activity,
contributing to alterations in pain perception. In particu-
lar, patients with Val/Val homozygous genotype require
more morphine than Val/Met heterozygous or Met/Met
homozygous (reviewed by Allegri et al. 2010).
Morphine glucuronides: Blood Brain Barrier
penetration
In humans, morphine undergoes a variety of metabolic path-
ways, the most important of which involve the
glucuronidation of the 3-OH phenolic group and of the 6-
OH alcoholic group to yield morphine 3-O-β-D-glucuro-
nide (M3G) and morphine 6-O-β-D-glucuronide (M6G),
respectively. Both reactions occur in the liver microsomes;
3-glucuronidation predominates over 6-glucuronidation for
the natural (−)-morphine, while the reverse occurs for the
unnatural (+)-morphine (Coughtrie et al. 1989).
Following oral administration of morphine to patients,
the M6G and M3G plasma AUC (Area Under the
concentration-time Curve) exceeds that of the parent drug
by factors of 9:1 and 50:1, respectively (Osborne et al.
1990). However, while M3G is not a specific ligand for
OPRM1, the receptor shows an affinity for M6G that can
be lower than or similar to that of morphine (Christensen
and Jǿrgensen 1987). Most of the analgesic effect of mor-
phine treatment is due to the M6G metabolite rather than to
morphine itself; accordingly, thanks to its higher potency
and less marked respiratory depressive effects, M6G could
be a more attractive analgesic compared to the parent drug.
The analgesic activity of M6G is extremely potent following
intracerebroventricular administration but markedly lower
than morphine following systemic administration, due to
poor BBB permeability to M6G. Several hypotheses have
been advanced to explain this low permeability: one of them
relates M6G weak capacity to cross the BBB by passive
diffusion to the molecule hydrophilicity. In rats, M6G has
been found to be 7.5 times less permeable through the BBB
than morphine and similar to sucrose, which is considered as
not crossing the BBB (Yoshimura et al. 1973). Another
explanation derives from more recent studies suggesting that
BBB permeability of M6G is restricted by an efflux mech-
anism (Bouw et al. 2001). Lötsch et al. (2001) demonstrat-
ed, in two strains of mice, the non-influence of P-
glycoprotein (P-gp) on M6G pharmacodynamics. This find-
ing was confirmed and further investigated by Bourasset et
al. (2003), who co-perfused, in wild-type and P-gp-deficient
mice, M6G with digoxin or PSC833, two substrates of
Oatp2 transporters; the authors confirmed the absence of
M6G transport by P-gp and suggested that M6G is actively
transported by a digoxin-sensitive transporter at the BBB
level. As Oatp2 is thought to be expressed at both the
luminal and basolateral sides of the brain endothelial cells,
and to bidirectionally transport its substrates, it can actively
transport M6G from blood to brain.
More recent studies (Fujita et al. 2010) in cancer patients
have supported the hypothesis that efflux transporter P-
glycoprotein (ATP-binding cassette, subfamily B, member
1 (ABCB1)) is a major determinant of the intracellular
concentration of morphine and its two main metabolites.
ABCB1 pumps the drug out the central nervous system
and has a fundamental role in its BBB disposition. Sai et
al. (2006) identified a variety of ABCB1 polymorphisms
and, more recently, Campa and coworkers (2008)
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significantly associated with 3435C>T variant. On the other
hand no relation was found between morphine-induced ad-
verse events and ABCB1 polymorphisms.
In a previous study (Lötsch et al. 2002a, b), PSC833 drug
was found to increase threefold the interstitial spinal cord
level of M6G, in contrast with its transport decrease across
the BBB. These apparently discrepant effects of PSC833 on
M6G may be associated with the different CNS regions
analyzed in the two studies: indeed, anatomically and kinet-
ically, there is no reason to expect a parallel behavior of
M6G at two distinct CNS barriers, i.e. the BBB and the
blood-spinal cord barrier.
M3G, the non-active morphine metabolite, is structurally
very similar to M6G, but its transport across the BBB is
quite different: for example, probenecid (a substrate for
anionic transporters) does not significantly influence M6G
pharmacokinetics, but increases the M3G brain/blood ratio
from 0.08 to 0.16 (Xie et al. 2000). An explanation could lie
in the different affinity of the two metabolites for the recep-
tors: different from M6G, M3G does not bind μ-, δ- and κ-
opioid receptors (Ulens et al. 2001).
The binding of opioid peptides with β-D-glucose by an
O-β-linkage has been shown to enhance their brain pene-
tration via the glucose transporter GLUT-1 pathway; accord-
ingly, Polt et al. (1994) suggested that M6G could also cross
the BBB by binding the GLUT-1 transporter. This hypoth-
esis was confirmed by Dagenais et al. (2000), who co-
perfused P-gp competent and deficient mice with a solution
of D-glucose (at a concentration high enough to saturate
GLUT-1). Irrespective of the mice phenotype, they found
that M6G brain uptake was significantly decreased. This
finding indicates that M6G can cross the BBB via GLUT-
1, the same transporter of D-glucose. Like Oatp2, GLUT-1
is expressed on both sides of the brain microvessel endo-
thelial cells and is known to transport glucose by a facilitat-
ed passive diffusion pathway. Considering the very low
brain uptake, Bourasset et al. (2003) suggested that M6G
may be transported from blood to brain and vice versa
(according to its concentration gradient) by GLUT-1 and
by a digoxin-sensitive transporter (possibly Oatp2) with a
weak transport capacity.
Brain penetration can also occur by passive transport,
which is difficult to correlate with the two highly polar and
hydrophilic morphine conjugates. However, it was ob-
served that the two glucuronides (as zwitterions) exist in
a conformational equilibrium between extended and folded
forms. The extended conformers, by exposing their polar
groups, are highly hydrophilic and predominate in polar
media, such as water. In contrast, folded conformers mask
part of their polar groups and result more lipophilic in
low-polarity media, such as biological membranes
(Carrupt et al. 1991). M6G, rather than M3G, prefers
the folded form in both neutral and anionic states, be-
cause this conformer presents a strong hydrogen bond
between the 3-phenolic group and the carboxylic/carbox-
ylate group. The possibility for morphine glucuronides to
adapt their polarity to that of the medium could account
for their comparatively good brain penetration and slow
urinary excretion.
Conclusions
Morphine is one of the most important and widely used
opioid for the treatment of chronic and acute pain: the very
wide interindividual variability in the patients’ response to
the drug may have genetic derivations.
Metabolic pathway (glucoronidation reactions in the
liver), sites of action (μ-opioid receptor) and elimina-
tion (efflux from BBB) are regulated by enzymes with
an activity that, in many circumstances, is directly
related to adverse reactions. It’s not yet clear if
UGT2B7 genetic polymorphisms—affecting pharmaco-
kinetics—can also cause strong side effects; on the
contrary, it was observed that cancer patients homozy-
gous for OPRM1 G allele (A118G) are poor responders
to morphine, and require higher doses of the drug to
relieve pain. In addition, morphine and its metabolites
have to cross the BBB and penetrate the CNS to
perform their activity: it was demonstrated that pain
relief variability, in cancer patients, is significantly as-
sociated with a ABCB1 gene variant. The current liter-
ature clearly indicates that both influx and efflux
activities, as well as carrier binding, need to be more
thoroughly addressed.
Morphine and its metabolites have a very different
ADME profile. The ADME differences are perhaps
most likely to explain some of the differences but seem
unlikely to be the whole story. We have reviewed the
rather scattered literature available on the mechanisms
of transport of morphine and its glucuronides (M3G-
M6G) through the BBB. We believe that a deep under-
standing of this mechanism, from physical, biochemical
and genetic points of view, could improve morphine
administration by helping decrease adverse reactions
and customize patient pain therapy.
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